Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)

Stratigos, A. J.Sekulic, A.Peris, K.Bechter, O.Dutriaux, C.Kaatz, M.Lewis, K. D.Basset-Seguin, N.Chang, A. L. S.Dalle, S.Fernandez-Orland, A.Licitra, L.Robert, C.Ulrich, C.Hauschild, A.Migden, M. R.Dummer, R.Li, S.Bowler, T.Fury, M. G.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27616enPrimary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)conference outputopen access10.1016/j.annonc.2020.08.22771569-8041http://www.annalsofoncology.org/article/S0923753420423592/pdf573469102675